Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Regulatory Network Reaches ‘Point Of No Return,’ German Official Says Of Brexit

Executive Summary

A senior German regulator says that changes the EU medicines regulatory network has been making since the UK announced it was leaving the EU means that nothing will ever be the same again irrespective of whether the UK is allowed to remain in network as part of a Brexit deal.

You may also be interested in...



Germany Heads List Of EU Countries Taking On UK’s RMS Roles

Companies still need to replace the UK as their reference member state for around 6,000 products in Europe’s decentralized and mutual recognition procedures. Of the switches that have been completed so far, many have gone to Germany.

UK Wants ‘Associate Membership’ Of The EMA After Brexit, Prime Minister Says

The UK prime minister Theresa May says that the UK will seek “associate membership” of the European Medicines Agency after Brexit, an announcement that has been welcomed by the UK life sciences industry. However, it remains to be seen what this would entail in terms of UK regulatory input, and whether the EU will agree to negotiating such a status for a departing member state.

MEPs To Visit Amsterdam To Check On EMA Relocation Progress

Members of the European Parliament are heading to the Netherlands to see whether the European Medicines Agency’s relocation process is going according to plan. The move follows Italian criticisms that the Dutch provided “incomplete” information about their readiness to host the agency.

Related Content

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel